A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment

<i>Objective: </i>To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. <i>Methods: </i>140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. <i>Results: </i>The incidences of CIN for iohexol and ioversol were not significantly different (<I>P </I>> 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (<I>P </I>> 0.05) ; the changes of Scr, β<sub>2</sub>-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (<I>P</I><0.05), but the change of BUN was not significant (<I>P </I>> 0.05).Through multiple regression analysis, it was found that type 2 diabetes (<I>OR</I> = 9.560, <I>P</I>=0.001), two coronary artery implanting stents (<I>OR</I> = 6.252, <I>P</I>=0.044), three and above coronary artery implanting stents (<I>OR</I>=12.499, <I>P</I>=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (<I>P</I>>0.05). <i>Conclusion:</i> There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.